Dr. Jatinder Kapur appointed as VP of Quality

Appointment builds Oxular’s team as it prepares to enter human clinical studies evaluating OXU-001

OXFORD, UK, 8 February 2021 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces that it has appointed Dr. Jatinder Kapur as Vice President of Quality.

His primary responsibilities include establishing and managing the Company’s Quality Management System, while also supporting other functions, as the Company prepares to enter human clinical studies evaluating OXU-001. OXU-001 is the Company’s 12-month treatment for inflammatory retinal diseases initially being evaluated for the treatment of Diabetic Macular Edema (DME). Dr. Kapur has been working with the Company as a consultant and will now join on a full-time basis.

Dr. Kapur has more than 20 years of experience in the quality assurance function, amassing extensive knowledge in the development of both pharmaceuticals, including sterile injectables, oral dosage forms, liquid suspension preparations, and medical devices. Dr. Kapur has worked with several quality pharmaceutical companies, such as Novartis, Shire Pharmaceuticals and BTG plc, and has significant experience working with combination medical device and pharmaceutical products. Dr. Kapur has overseen product technology transfers, designed and commissioned a sterile API plant, and actively led the establishment of numerous quality management systems, including efforts at Nicholas Piramal Pharma and Nectar Lifesciences. He obtained a Ph.D. in Organic Chemistry at Punjab University in 1997 and acquired QP qualification in 2019 from the Royal Society of Chemistry.

Thomas Cavanagh, Chief Executive Officer of Oxular commented:

“I am delighted for Jatinder to join Oxular and strengthen our management team. Jatinder has made significant contributions to the Company already and I am certain he will ensure that the highest standards of quality are maintained across our development pipeline. This will be especially important as the Company prepares OXU-001 to enter human clinical studies for the treatment of DME later this year.”

Ron Yamamoto, Chief Scientific Officer of Oxular commented:

“Jatinder has played a critical role in the Oxular development team, supporting our efforts with his extensive expertise in quality assurance, manufacturing transfer and analytical chemistry. His broad skill set allows him to contribute across all of Oxular’s programs.”

Dr. Jatinder Kapur, Vice President of Quality of Oxular said:

“I am very excited to be joining Oxular at this stage in the Company’s development. I look forward to using my years of experience in the pharmaceutical and medical device industry to help Oxular maximize the potential of its innovative sustained release drug formulation and ocular administration technology and highly differentiated product pipeline.”

Enquiries

Media Contact

Ben Atwell / Alex Davis

FTI Consulting,
200 Aldersgate,
Aldersgate Street,
London, EC1A 4HD, UK

T: +44 (0)20 3727 1000

E: oxular@fticonsulting.com


About Oxular Limited

“One treatment a year. Life changing.”

 

Oxular is developing disruptive technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally-invasive delivery. This novel combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema and age-related macular degeneration, as well as rare and orphan indications, including treatments for ocular cancers.

Oxular Logo
Scroll to Top